## Amendments to the Specification

Please replace the paragraph at page 16, lines 2-20 with the following replacement paragraph:

(3) The tested compound having desired concentration was reacted in the solution of 20mM tris-HCl (pH 7.5), 1mM of MgCl<sub>2</sub>, 100 μM of EDTA, 330 μg/mL of bovine serum albumin, 4μg/mL of 5'-nucleotidase, 0.1 μCi of <sup>3</sup>H-cAMP (0.064 μM of cAMP), 10 μM of rolipram in storage solution of PDE 7 for 2 hours at 25°C. After the reaction, suspension of Sephadex SEPHADEX®-QAE (cross-linked dextran gel) in 10mM of HEPES-Na (pH 7.0) was added to the reaction mixture, and the mixture was left at rest for 5 minutes. Further, Sephadex SEPHADEX®-QAE (cross-linked dextran gel) was added to the obtained supernatant and the mixture was leaved at rest for 5 minutes, then, the radioactivity of the solution was measured.

Please replace the paragraph at page 17, lines 11-20 with the following replacement paragraph:

(1) The active fraction of PDE 4 (phosphodiesterase IV) was obtained. That is, the livers obtained from three Balb/c mice (male, 12 weeks: obtainable from CLEA Japan, Inc.) were suspended with 30mL of buffer solution B [20mM of bis-tris, 5mM of 2-mercaptoethnol, 2mM of benzamidine, 2mM of EDTA, 0.1mM of 4-(2-aminoethyl)benzensulfonyl hydrochloride, 50mM of sodium acetate; pH 6.5], then homogenized by Polytron POLYTRON® homogenizer. The homogenate were centrifuged under 25,000 × G for 10 minutes at 4°C. The supernatant was separated and thus obtained supernatant was further centrifuged under 100,000 × G for 60 minutes at 4°C, and then filtrated with 0.2 μm filter to obtain the soluble fraction.

Please replace the paragraph at page 17, line 30 to page 18, line 6 with the following replacement paragraph:

(3) The tested compound having desired concentration was reacted in the solution of 20mM tris-HCl (pH 7.5), 1mM of MgCl<sub>2</sub>, 100 μM of EDTA, 330 μg/mL of bovine serum albumin, 4 μg/mL of 5'-nucleotidase, 0.1μCi of <sup>3</sup>H-cAMP (0.064 μM of cAMP), and storage solution of PDE 4 for 2 hours at 25°C. After the reaction, suspension of Sephadex SEPHADEX®-QAE (cross-linked dextran gel) in 10mM of HEPES-Na (pH 7.0) was added to the reaction mixture, and the mixture was left at rest for 5 minutes. Further, Sephadex SEPHADEX®-QAE (cross-

PATENT APPLICATION No. 10/560,503 ATTORNEY DOCKET: 69681.000006

<u>linked dextran gel</u>) was added to the obtained supernatant and the mixture was left at rest for 5 minutes, then, the radioactivity of the solution was measured.

Please replace the paragraph at page 23, line 23 to page 16, line 1 with the following replacement paragraph:

(1) The active fraction of PDE 7 (phosphodiesterase VII) was obtained. That is, MOLT-4 (obtainable from ATCC as ATCC No. CRL-1582), which was cell line of human acute lymphoblastic lymphoma T cells, was incubated in RPMI1640 culture medium containing 10% fetal bovine serum to obtain 5 × 10<sup>8</sup> MOLT-4 cells. The cells were collected by centrifugation and suspended with 10mL of buffer solution A [25mM of tris-HCl, 5mM of 2-mercaptoethnol, 2mM of benzamidine, 2mM of EDTA, 0.1mM of 4-(2-aminoethyl)benzensulfonyl hydrochloride; pH 7.5], then homogenized by Polytron POLYTRON® homogenizer. The homogenate were centrifuged under 25,000 × G for 10 minutes at 4°C. The supernatant was separated and thus obtained supernatant was further centrifuged under 100,000 × G for 60 minutes at 4°C, and then filtrated with 0.2 μm filter to obtain the soluble fraction.